South Korea’s pharmaceutical companies Boryung Corp. and HK inno.N announced on Wednesday that they will start co-marketing for their respective blockbuster drugs Kanarb and K-CAB in January next year.
This deal is the first collaboration between domestic pharmaceutical companies that have developed blockbuster new drugs with annual sales exceeding 100 billion won ($76.98 million).
Under the agreement, Boryung will take over marketing for all K-CAB products, including tablets and orally disintegrating tablets. HK inno.N will manage the four types of Kanarb: Kanarb, Dukaro, Dukarb, and Dukarb Plus.
Medical Market research firm UBIST reports that K-CAB, a treatment for gastroesophageal reflux disease, recorded sales of 132.1 billion won ($101 million) last year. Meanwhile, Kanarb, a hypertension treatment, generated 150.3 billion won ($115 million) in 2022 across seven product variations.
South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophageal reflux disease (GERD) drug K-CAB.K-CAB, expected to exceed 100 billion won ($76.2 million) in sales this year, is a blockbuster drug for HK in
South Korea’s Boryung Corp. on Tuesday said it received approval from the Ministry of Food and Drug Safety for its new compound diabetes drug Trubuddy.This new and improved medicine combines two active ingredients: the SGLT-2 inhibitor dapagliflozin and thiazolidinedione (TZD)-class piog
South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in Indonesia, the largest market in Southeast Asia.HK inno.N announced on Monday that it has launched the GERD drug K-CAB (generic name: Tegoprazan) in
Boryung Biopharma's typhoid vaccine Zerotyph (Courtesy of Boryung Biopharma) Dongwon Industries Co., South Korea’s No. 1 canned tuna producer, has backed out of a deal estimated between $400 million and $500 million to buy Boryung Biopharma Co., a vaccine and novel drug developer, accordi
Boryung's lab at its Yesan plant (Courtesy of Boryung) South Korea's Boryung Corp., just decades ago a mom-and-pop pharmacy, will bring its healthcare expertise to space with Axiom Space Inc., a US commercial space station developer, dreaming to become a pioneer in the market for healthcare ser
HK Inno.N's K-CAB South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegoprazan) has been approved by the Mexican Ministry of Health. This marks the first approval of the treatment in a Latin American cou